Perfusion Change of Hepatocellular Carcinoma During Atezolizumab plus Bevacizumab Treatment: A Pilot Study
ConclusionThe early change in HCC perfusion may predict the long-term therapeutic response to atezolizumab plus bevacizumab, promoting personalized treatment for HCC patients.
Source: Journal of Gastrointestinal Cancer - Category: Cancer & Oncology Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Carcinoma | Gastroenterology | Hepatocellular Carcinoma | Liver | Liver Cancer | Perfusion | Statistics | Study | Urology & Nephrology